title: [Advances of PD-1/PD-L1 signaling pathway in immune escape and treatment for  non-small cell lung cancer].
abstract: Lung cancer is the leading cause of cancer-related mortality worldwide. Despiting the great progress on target agents, majority of people who do not harbor a mutation could not get benefit from them. Immunotherapy, through stimulating the body's immune system to improve the antitumor immunity effect, has been a new therapeutic method for non-small cell lung cancer (NSCLC). Study had been reported that immune checkpoint molecules, including programmed death-1 (PD-1)/PD-ligand (L) 1 axis, are closedly related with cancer generation and development, and play a key role on clinical significance of NSCLC. Activation of PD-1/PD-L1 pathway contributes to tumor immune escape, and block PD-1/PD-L1 pathway can enhance endogenous antimuor immunity. Currently increasing clinical trials suggested that immune checkpoint inhibitors, including anti-PD-1 and anti-PD-L1 monoclonal antibodies turned out to be beneficial and safe in NSCLC. Here, we provide a review on the progress of PD-1/PD-L1 pathway and immune checkpoint inhibitors in NSCLC.
authors.affiliation: Nanjing Military Command Fuzhou General Hospital, Fuzhou 350025, China.
authors.forename: Cheng
authors.initials: C
authors.lastname: Lin
authors.affiliation: Nanjing Military Command Fuzhou General Hospital, Fuzhou 350025, China.
authors.forename: Xiong
authors.initials: X
authors.lastname: Chen
authors.affiliation: Nanjing Military Command Fuzhou General Hospital, Fuzhou 350025, China.
authors.forename: Jingnan
authors.initials: J
authors.lastname: Liu
authors.affiliation: Nanjing Military Command Fuzhou General Hospital, Fuzhou 350025, China.
authors.forename: Yufang
authors.initials: Y
authors.lastname: Huang
authors.affiliation: Nanjing Military Command Fuzhou General Hospital, Fuzhou 350025, China.
authors.forename: Xuenong
authors.initials: X
authors.lastname: Ou-Yang
mesh_terms: D000818:Animals; D060890:B7-H1 Antigen / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D061026:Programmed Cell Death 1 Receptor / Q000378:metabolism*; D015398:Signal Transduction / Q000276:immunology*; D019139:Tumor Escape
chemical_list: D060890:B7-H1 Antigen; C423236:CD274 protein, human; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor